Bicara Therapeutics Inc. (BCAX) is a clinical-stage biotechnology company, not an ETF, focused on bifunctional antibody therapies for solid tumors. Its coverage is modest but active, and the analyst community is sharply divided. Reviewing the most recent published targets for seven analysts produces a range of roughly $8 to $39, with a calculated mean near $26.86, rounded to $27.
The dispersion is striking. On the cautious side, Goldman Sachs carried a Sell rating with an $8 target, while Wells Fargo ($23) and Mizuho ($20) held neutral views. On the bullish side, Morgan Stanley and BTIG each carried $39 targets, with BMO Capital at $35 and Wedbush at $24. This is not a tight consensus; it is a split between analysts who see the lead program eventually justifying a multi-billion-dollar valuation and those who see the stock as already fairly or over-valued. The wide gap means the $27 figure is a midpoint of very different scenarios, not a prediction most analysts are clustered around.
The stock closed near $9.99 on November 9, 2026, down sharply from its 52-week high of $30.99 set in mid-2026 and only modestly above its 52-week low of $7.87. Reaching $27 from $9.99 would require upside of roughly 170%, which qualifies as a very large move. Bicara generates no product revenue and posts ongoing net losses, so the entire path toward a higher valuation depends on clinical execution rather than earnings growth in the near term.
Bicara's lead asset, ficerafusp alfa, is a bifunctional antibody combining an EGFR-directed monoclonal antibody with a TGF-β ligand trap. The company transitioned its FORTIFI-HN01 program into a pivotal Phase 3 trial in early 2026, and three-year follow-up data presented in May 2026 indicated the therapy roughly doubled estimated survival compared with historical standard-of-care outcomes in head and neck cancer. Any durable move toward $27 would most likely need to be driven by additional positive data and eventual regulatory progress.
The stock sits well below its major moving averages, with the 50-day moving average near $18 and the 200-day moving average near $21, confirming a broken longer-term uptrend. The 52-week range of $7.87 to $30.99 frames the current position: $7.87 is the key support level to hold, while any recovery toward $27 would first need to reclaim the psychologically important $10 level and then work through the $18-to-$21 zone, which now acts as overhead resistance. The prior $30-plus high represents the most durable reference point for the bullish targets above $30.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual analysts apply different assumptions, particularly for a clinical-stage company whose value hinges on discrete data events rather than steady earnings. Investors should monitor upcoming trial readouts and enrollment milestones for FORTIFI-HN01, any regulatory or development updates on ficerafusp alfa, quarterly cash position and spending, and any analyst rating or target changes. Additional financing activity, if pursued, would also be material to the share count and valuation.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like BCAX, this kind of automated monitoring can help traders spot changing trends, track positions, and surface opportunities more efficiently than manual chart review. Traders can use the signals to complement their own research and stay responsive to fast-moving conditions.
The question of whether BCAX can reach $27 ultimately comes down to clinical execution. The $27 figure is the average of seven analyst targets spanning $8 to $39 — a midpoint that reflects a wide split between bullish and bearish scenarios rather than a tightly held consensus. Reaching it from near $10 would require a roughly 170% move, a very large advance that would almost certainly need positive pivotal-trial data and renewed investor confidence after a punishing drawdown. The bull case rests on ficerafusp alfa's survival data and a strong cash runway; the bear case rests on clinical risk, heavy losses, and the stock's broken technical trend. Neither outcome is assured, and investors should watch trial readouts, cash position, and analyst revisions closely before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, BCAX has been loosely correlated with RAPP. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BCAX jumps, then RAPP could also see price increases.
| Ticker / NAME | Correlation To BCAX | 1D Price Change % | ||
|---|---|---|---|---|
| BCAX | 100% | +2.00% | ||
| RAPP - BCAX | 53% Loosely correlated | -0.42% | ||
| INBX - BCAX | 46% Loosely correlated | -1.23% | ||
| RCUS - BCAX | 44% Loosely correlated | -1.48% | ||
| SION - BCAX | 40% Loosely correlated | +3.64% | ||
| RGNX - BCAX | 38% Loosely correlated | -4.71% | ||
More | ||||